LGP5 LOA
Toripalimab by Shanghai Junshi Bioscience for Leiomyosarcoma: Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Bioscience and currently in Phase II for Leiomyosarcoma. According to GlobalData, Phase…
TQB-2618 by Chia Tai Tianqing Pharmaceutical Group for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
TQB-2618 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase II for Squamous Non-Small Cell…
Trecondyv by Medac for Hematopoietic Stem Cell Transplantation: Likelihood of Approval
Trecondyv is under clinical development by Medac and currently in Pre-Registration for Hematopoietic Stem Cell Transplantation. According to GlobalData, Pre-Registration…
TRGFT-201 by Orca Biosystems for Myelodysplastic Syndrome: Likelihood of Approval
TRGFT-201 is under clinical development by Orca Biosystems and currently in Phase III for Myelodysplastic Syndrome. According to GlobalData, Phase…
TSC-100 by TScan Therapeutics for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
TSC-100 is under clinical development by TScan Therapeutics and currently in Phase I for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic…
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
TT-816 by Teon Therapeutics for Solid Tumor: Likelihood of Approval
TT-816 is under clinical development by Teon Therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase…
Tusamitamab ravtansine by Sanofi for Small-Cell Lung Cancer: Likelihood of Approval
Tusamitamab ravtansine is under clinical development by Sanofi and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData,…
UBX-1325 by Unity Biotechnology for Diabetic Macular Edema: Likelihood of Approval
UBX-1325 is under clinical development by Unity Biotechnology and currently in Phase II for Diabetic Macular Edema. According to GlobalData,…
Ulixertinib by BioMed Valley Discoveries for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval
Ulixertinib is under clinical development by BioMed Valley Discoveries and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC).…
UWC-19 by UWELL Biopharma for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
UWC-19 is under clinical development by UWELL Biopharma and currently in Phase I for Chronic Lymphocytic Leukemia (CLL). According to…